Actionable news
0
All posts from Actionable news
Actionable news in GILD: Gilead Sciences, Inc.,

Gilead: - Product Sales Of

The following excerpt is from the company's SEC filing.

$7.7 billion

- GAAP Diluted EPS of

per share -

- Non-GAAP Diluted EPS of

- Reiterates Full Year 2016 Guidance -

Foster City, CA,

April 28, 2016

- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the

first quarter

ended

. The financial results that follow represent a year-over-year comparison of

to the

. Total revenues were

$7.8 billion

compared to

$7.6 billion

. Net income was

$3.6 billion

per diluted share in

$4 .3 billion

. Non-GAAP net income, which excludes acquisition-related, up-front collaboration, stock-based compensation and other expenses, was

$4.6 billion

Three Months Ended

March 31,

(In millions, except per share amounts)

Product sales

Royalty, contract and other revenues

Net income attributable to Gilead

Non-GAAP net income attributable to Gilead

Non-GAAP diluted EPS

Product Sales

Total product sales for the

first quarter of 2016

$7.4 billion

for the same period in

Product sales for the

$4.4 billion

in the U.S.,

$1.6 billion

in Europe,

$1.1 billion

in Japan and

$571 million

in other international locations. Product sales for the

first quarter of 2015

$5.2 billion

$1.8 billion

in Europe and

$364 million

- more -

Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA

www.gilead.com

phone (650) 574-3000 facsimile (650) 578-9264

April 28, 2016

Antiviral Product Sales

Antiviral product sales, which include products in our HIV and liver disease areas, were

$7.2 billion

$7.0 billion

In the U.S., antiviral product sales were

$4.0 billion

$4.9 billion

, primarily due to a decline in sales of Harvoni

(ledipasvir 90 mg/sofosbuvir 400 mg), partially offset by increases in sales of Sovaldi

(sofosbuvir 400 mg), Truvada

(emtricitabine and tenofovir disoproxil fumarate) and Genvoya

(elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg). Genvoya was launched in the U.S. in November 2015.

In Europe, antiviral product sales were

$1.7 billion

, primarily due to a decline in sales of Sovaldi.

In Japan, antiviral product sales were

. Sovaldi and Harvoni were launched in Japan in May and September 2015, respectively.

Other Product Sales

Other product sales, which include Letairis

(ambrisentan), Ranexa

(ranolazine) and AmBisome

(amphotericin B liposome for injection), were

$498 million

$417 million

Cost of Goods Sold

Non-GAAP* cost of goods sold increased to

$983 million

$674 million

, primarily due to a $200 million litigation charge related to our sofosbuvir based product sales.

Operating Expenses

(In millions)

Non-GAAP* research and development expenses (R&D)

Non-GAAP* selling, general and administrative expenses (SG&A)

Non-GAAP Cost of Goods Sold, R&D and SG&A expenses exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses

During the

, compared to the same period in

Non-GAAP research and development expenses increased primarily due to the progression of Gilead's clinical studies.

Non-GAAP selling, general and administrative expenses increased primarily due to higher costs to support Gilead's geographic expansion of its business, partially offset by a decrease in our Branded Prescription Drug fee expense.

Cash, Cash Equivalents and Marketable Securities

As of

, Gilead had

$21.3 billion

of cash, cash equivalents and marketable securities compared to

$26.2 billion

as of December 31, 2015. During the

, we utilized

$8.0 billion

on stock repurchases and made an upfront license fee payment of $300 million and an equity investment of $425 million related to our license and collaboration agreement with Galapagos NV. Cash flow from operating activities was

$3.9 billion

for the quarter.

Gilead reiterates its full year 2016 guidance, initially provided on February 2, 2016:

(In millions, except percentages and per share amounts)

Provided

Net Product Sales

$30,000 - $31,000

Product Gross Margin

88% - 90%

R&D expenses

$3,200 - $3,500

$3,300 - $3,600

Effective Tax Rate

18.0% - 20.0%

Diluted EPS Impact Related to Acquisition, Up-front Collaboration, Stock-based Compensation and Other Expenses

$1.10 - $1.16

* Non-GAAP Product Gross Margin, R&D and SG&A expenses and effective tax rate exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses.

Corporate Highlights

Announced that Chairman and Chief Executive Officer (CEO) John C. Martin, PhD assumed the role of Executive Chairman of the company. John F. Milligan, PhD, formerly President and Chief Operating Officer, was promoted to President and CEO, effective March 10, 2016, and appointed to the company’s Board of Directors.

Announced that Gilead will provide grants for up to three years to academic institutions, nonprofit organizations and community groups engaged in HIV cure activities. The unrestricted grants are awarded to organizations with a track record of excellence in results-driven research.

Announced that the Board of Directors approved the repurchase of an additional $12 billion of the company’s common stock which commenced upon completion of the company’s existing $15 billion repurchase program authorized in January 2015.

Product & Pipeline Updates announced by Gilead during the

First Quarter

include:

Announced that U.S. Food and Drug Administration (FDA) approved Odefsey

(emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Emtricitabine and tenofovir alafenamide are from Gilead while rilpivirine is from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Odefsey is Gilead’s second TAF-based regimen to receive FDA approval and represents the smallest pill of any single-tablet regimen available today for the treatment of HIV.

Announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for two doses of Descovy

(emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), an investigational fixed-dose combination for the treatment of HIV-1 infection in adults and adolescents (ages 12 years and older with body weight at least 35 kg) in combination with other HIV antiretroviral agents.

Presented data at the 2016 Conference on Retroviruses and Opportunistic Infections, which included the announcement of:

48-week results from a Phase 3 study (Study 1089) evaluating the safety and efficacy of switching virologically suppressed HIV-1 infected adult patients from regimens containing Truvada to regimens containing the investigational fixed-dose combination of emtricitabine and F/TAF. At Week 48, the F/TAF-based regimens were found to be statistically non-inferior to the emtricitabine and tenofovir disoproxil fumarate (F/TDF) -based regimens, based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. The study also demonstrated statistically significant improvements in renal and bone laboratory parameters among patients receiving F/TAF-based regimens.

Results from a preclinical study conducted in collaboration with researchers at Beth Israel Deaconess Medical Center evaluating a proprietary investigational oral toll-like receptor 7 (TLR7) agonist, GS-9620, and a related molecular analogue, GS-986, as part of an HIV eradication strategy. Data from the study conducted in simian immunodeficiency virus (SIV)-infected virally suppressed rhesus macaques on antiretroviral therapy (ART) demonstrate that TLR7 agonist treatment induced transient plasma SIV RNA blips and reduced SIV DNA. In addition, TLR7 agonist treatment resulted in subsequent prolonged virus suppression in some of the macaques after stopping ART.

Announced that the company’s Type II variation application for once-daily Truvada in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, a strategy known as pre-exposure prophylaxis or PrEP, was fully validated and under evaluation by the EMA.

Announced that the company’s MAA for TAF 25 mg, an investigational, once-daily treatment for adults with chronic hepatitis B virus (HBV) infection, was fully validated and under assessment by the EMA. The company also submitted a new drug application (NDA) to FDA for TAF 25 mg for the treatment for adults with chronic HBV infection.

Announced that FDA approved two supplemental indications for Harvoni for use in chronic hepatitis C patients with advanced liver disease. Harvoni in combination with ribavirin for 12 weeks was approved for use in chronic hepatitis C virus (HCV) genotype 1- or 4-infected liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and for HCV genotype 1-infected patients with decompensated cirrhosis (Child-Pugh B or C), including those who have undergone liver transplantation. Harvoni is approved for use in HCV genotypes 1, 4, 5 and 6, HCV/HIV-1 coinfection, HCV genotype 1 and 4 liver transplant recipients, and genotype 1-infected patients with decompensated cirrhosis.

Announced that FDA granted priority review to the company’s NDA for an investigational once-daily fixed-dose combination of sofosbuvir and velpatasvir (SOF/VEL), for the treatment of chronic genotype 1-6 HCV infection. FDA has set a target action date under the Prescription Drug User Fee Act of June 28, 2016.

Conference Call

At 4:30 p.m. Eastern Time today, Gilead's management will host a conference call and a simultaneous webcast to discuss results from its

as well as provide a general business update. To access the webcast live via the internet, please connect to the company's website at

www.gilead.com/investors

15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the conference ID 76639018 to access the call.

A replay of the webcast will be archived on the company's website for one year, and a phone replay will be available approximately two hours following the call through April 30, 2016. To access the phone replay, please call 1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the conference ID 76639018.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Non-GAAP Financial Information

Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (GAAP) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 8.

Forward-looking Statements

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2016 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; the possibility of unfavorable results from clinical trials involving investigational compounds, including GS-9620 and GS-986; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including SOF/VEL and TAF for the treatment of chronic HBV; Gilead's ability to successfully commercialize its products, including Genvoya, Odefsey and Descovy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; the risk that estimates of patients with HCV or anticipated patient demand may not be accurate; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Sovaldi and Harvoni; Gilead's ability to successfully develop its oncology, inflammation, cardiovascular and respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates; the potential for pricing pressure from additional competitive HCV launches or austerity measures in European countries and Japan that may increase the amount of discount required on Gilead's products; Gilead's ability to complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (SEC). In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal, or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its press releases, Annual Report on Form 10-K for the year ended December 31, 2015 and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Gilead owns or has rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD

, GILEAD SCIENCES

, AMBISOME

, CAYSTON

, COMPLERA

, DESCOVY

EMTRIVA

, EVIPLERA

, GENVOYA

, HARVONI

, HEPSERA

, LETAIRIS

, ODEFSEY

, RANEXA

, RAPISCAN

, SOVALDI

, STRIBILD

, TRUVADA

, TYBOST

, VIREAD

, VITEKTA

, VOLIBRIS

, and ZYDELIG

ATRIPLA

is a registered trademark belonging to Bristol-Myers Squibb & Gilead Sciences, LLC. LEXISCAN

is a registered trademark belonging to Astellas U.S. LLC. MACUGEN

is a registered trademark belonging to Eyetech, Inc. SUSTIVA

is a registered trademark of Bristol-Myers Squibb Pharma Company. TAMIFLU

is a registered trademark belonging to Hoffmann-La Roche Inc.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or

call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(in millions, except per share amounts)

Revenues:

Product sales

Royalty, contract and other revenues

Total revenues

Costs and expenses:

Cost of goods sold

Research and development expenses

Selling, general and administrative expenses

Total costs and expenses

Income from operations

Interest expense

Other income (expense), net

Income before provision for income taxes

Provision for income taxes

Net income

Net income (loss) attributable to noncontrolling interest

Net income attributable to Gilead

Net income per share attributable to Gilead common stockholders - basic

Shares used in per share calculation - basic

Net income per share attributable to Gilead common stockholders - diluted

Shares used in per share calculation - diluted

Cash dividends declared per share

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(in millions, except percentages and per share amounts)

Cost of goods sold reconciliation:

GAAP cost of goods sold

Acquisition related-amortization of purchased intangibles

Stock-based compensation expenses

Non-GAAP cost of goods sold

Product gross margin reconciliation:

GAAP product gross margin

Non-GAAP product gross margin

Research and development expenses reconciliation:

Up-front collaboration expenses

Acquisition related-IPR&D impairment

Selling, general and administrative expenses reconciliation:

Operating margin reconciliation:

GAAP operating margin

Non-GAAP operating margin

Notes:

Amounts related to consolidation of a contract manufacturer, contingent consideration and/or other individually insignificant amounts

Amounts may not sum due to rounding

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)

Effective tax rate reconciliation:

GAAP effective tax rate

Non-GAAP effective tax rate

Net income attributable to Gilead reconciliation:

Diluted earnings per share reconciliation:

GAAP diluted earnings per share

Non-GAAP diluted earnings per share

Shares used in per share calculation (diluted) reconciliation:

GAAP shares used in per share calculation (diluted)

Share impact of current stock-based compensation rules

Non-GAAP shares used in per share calculation (diluted)

Non-GAAP adjustment summary:

Cost of goods sold adjustments

Research and development expenses adjustments

Selling, general and administrative expenses adjustments

Total non-GAAP adjustments before tax

Income tax effect

Total non-GAAP adjustments after tax attributable to Gilead

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions)

December 31,

Cash, cash equivalents and marketable securities

21,322

26,208

Accounts receivable, net

Inventories

Property, plant and equipment, net

Intangible assets, net

10,247

Goodwill

Other assets

Total assets

47,765

51,716

Current liabilities

10,910

Long-term liabilities

22,836

22,711

Equity component of currently redeemable convertible notes

Stockholders’ equity

14,019

19,113

Total liabilities and stockholders’ equity

(1)

Derived from the audited consolidated financial statements as of December 31, 2015. Certain amounts have been reclassified to conform to current presentation.

(2)

As of March 31, 2016, there were 1,348 million shares of common stock issued and outstanding.

PRODUCT SALES SUMMARY

(Unaudited)

Antiviral products:

Harvoni – U.S.

Harvoni – Europe

Harvoni – Japan

Harvoni – Other International

Sovaldi – U.S.

Sovaldi – Europe

Sovaldi – Japan

Sovaldi – Other International

Truvada – U.S.

Truvada – Europe

Truvada – Other International

Atripla – U.S.

Atripla – Europe

Atripla – Other International

Stribild – U.S.

Stribild – Europe

Stribild – Other International

Complera / Eviplera – U.S.

Complera / Eviplera – Europe

Complera / Eviplera – Other International

Viread – U.S.

Viread – Europe

Viread – Other International

Genvoya – U.S.

Genvoya – Europe

Genvoya – Other International

Other Antiviral – U.S.

Other Antiviral – Europe

Other Antiviral – Other International

Total antiviral products – U.S.

Total antiviral products – Europe

Total antiviral products – Japan

Total antiviral products – Other International

Total antiviral products sales

Other products:

Zydelig

Total product sales

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Gilead Sciences makes a similar move, sign up!

Other recent filings from the company include the following:

EVP of Gilead Sciences just disposed of 4,126 shares - April 21, 2016
Gilead: Fee Computed On Table Below Per Exchange Act Rules - April 8, 2016
EVP of Gilead Sciences just disposed of 5,000 shares - April 5, 2016
Gilead Sciences's Executive Chairman just cashed-in 100,000 options - April 5, 2016